<scp>Multi‐variable</scp> biomarker approach in identifying incident heart failure in chronic kidney disease: results from the Chronic Renal Insufficiency Cohort study

Janus, Scott E.; Hajjari, Jamal; Chami, Tarek; Mously, Haytham; Badhwar, Anshul K.; Karnib, Mohamad; Carneiro, Herman; Rahman, Mahboob; Al‐Kindi, Sadeer G.

doi:10.1002/ejhf.2543

Cited by 11 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum troponin T and nocturnal hypertension may be novel indicators associated with heart failure in patients. Recently, Janus et al ( 50 ) reported that a panel of brain natriuretic peptides, FGF-23, fibrinogen, and high-sensitive troponin T can be used to predict heart failure in patients with CKD. In addition, Fu et al ( 51 ) found that nocturnal hypertension is associated with LVH in patients with CKD, indicating that ambulatory blood pressure monitoring may be used as an important indicator to evaluate the risk of uremic cardiomyopathy.…”

Section: Discussionmentioning

confidence: 99%

A Bibliometric and Visualized Analysis of Uremic Cardiomyopathy From 1990 to 2021

Bao

She

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundUremic cardiomyopathy is commonly presented in chronic kidney disease (CKD), and it severely affects the prognosis of patients with CKD. In the past few decades, the investigation of uremic cardiomyopathy has developed rapidly. However, no report has summarized the situation of uremic cardiomyopathy research to date. This study aimed to evaluate the state of uremic cardiomyopathy research in the last 30 years and identify important topics and achievements, as well as emerging trends through bibliometric analysis.Materials and MethodsPublications related to uremic cardiomyopathy were collected from Science Citation Index Expanded. HistCite, VOSviewer, CiteSpace, and the Bibliometrix Package were used for bibliometric analysis and visualization, including the analysis of the overall distribution of the annual publication, leading countries, and active institutions and authors, core journals, co-cited references, and keywords.ResultsA total of 2,403 studies related to uremic cardiomyopathy were obtained, and progress related to uremic cardiomyopathy was slower in past 3 years. A total of 10,077 authors from 2,697 institutions in 89 countries or regions reported investigations on uremic cardiomyopathy. The United States of America was the most productive and the most cited country. Myles Wolf, Joseph I Shapiro, and Carmine Zoccali published most articles in uremic cardiomyopathy, and journals in nephrology possessed core status in the field. Phosphate metabolism was the hotspot in uremic cardiomyopathy research in recent years, and future progress may concentrate on phosphate metabolism, endogenous natriuretic factors, and novel biomarkers.ConclusionThe United States of America and European countries played central roles in uremic cardiomyopathy research, while Chinese scholars should be more involved in this field. Global publications on uremic cardiomyopathy have entered platform stage, and the fibroblast growth factor-23-klotho axis remained a hotspot in this field. Endogenous natriuretic factors and novel biomarkers may be potential directions in future investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

A Bibliometric and Visualized Analysis of Uremic Cardiomyopathy From 1990 to 2021

Bao

She

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Previous observational studies have demonstrated that the circulating concentration of FGF23 is related to heart failure (HF) (22,29,(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45), and this association appears to be stronger in patients with CKD (36,37,44,46), but is not affected by adjustment for kidney function (22,35,37,39,(41)(42)(43)(44). Some previous studies have shown significant relationships between high circulating FGF23 concentration and low ejection fraction (27,28,45,(47)(48)(49).…”

Section: Fgf23 and Heart Failurementioning

confidence: 99%

Direct and indirect effects of fibroblast growth factor 23 on the heart

2023

View full text Add to dashboard Cite

Fibroblast growth factor (FGF)23 is a bone-derived phosphotropic hormone that regulates phosphate and mineral homeostasis. Recent studies have provided evidence that a high plasma concentration of FGF23 is associated with cardiac disease, including left ventricular hypertrophy (LVH), heart failure, atrial fibrillation, and cardiac death. Experimental studies have shown that FGF23 activates fibroblast growth factor receptor 4 (FGFR4)/phospholipase Cγ/calcineurin/nuclear factor of activated T-cells signaling in cardiomyocytes and induces cardiac hypertrophy in rodents. Activation of FGFR4 by FGF23 normally requires the co-receptor α-klotho, and klotho-independent signaling occurs only under conditions characterized by extremely high FGF23 concentrations. Recent studies have demonstrated that FGF23 activates the renin-angiotensin-aldosterone system (RAAS) and induces LVH, at least in part as a result of lower vitamin D activation. Moreover, crosstalk between FGF23 and RAAS results in the induction of cardiac hypertrophy and fibrosis. In this review, we summarize the results of studies regarding the relationships between FGF23 and cardiac events, and describe the potential direct and indirect mechanisms whereby FGF23 induces LVH.

show abstract

“…Chronic kidney disease (CKD) is a major risk factor for HF 2,5 . Janus et al 6 . investigated the usefulness of biomarkers to predict the risk of HF in 3182 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC).…”

Section: Preventionmentioning

confidence: 99%

“…4 Chronic kidney disease (CKD) is a major risk factor for HF. 2,5 Janus et al 6 investigated the usefulness of biomarkers to predict the risk of HF in 3182 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC). Four biomarkers -B-type natriuretic peptide, fibroblast growth factor-23, fibrinogen and high-sensitivity troponin T -were associated with incident HF after adjustment for other risk factors and their inclusion allowed a better risk stratification for incident HF.…”

mentioning

confidence: 99%

June 2022 at a glance: prevention, outcomes and treatment

Tomasoni

Adamo

Metra

2022

European J of Heart Fail

View full text Add to dashboard Cite

Myocardial infarction (MI) is a major cause of heart failure (HF). [1][2][3] Rastogi et al. 4 showed different characteristics associated with the progression to HF in patients with or without a history of MI in the HOMAGE (Heart 'OMics' in AGEing) cohort. Older age, male sex and higher heart rate were associated with an increased risk of HF in all subjects, whereas lower renal function had a stronger association with HF in patients with a history of MI, and higher body mass index, hypertension and blood glucose were significant only in patients without a history of MI. These data were confirmed in the UK Biobank (validation cohort). 4 Chronic kidney disease (CKD) is a major risk factor for HF. 2,5 Janus et al. 6 investigated the usefulness of biomarkers to predict the risk of HF in 3182 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC). Four biomarkers -B-type natriuretic peptide, fibroblast growth factor-23, fibrinogen and high-sensitivity troponin T -were associated with incident HF after adjustment for other risk factors and their inclusion allowed a better risk stratification for incident HF. Acute myocarditisOutcomes of acute myocarditis are not clearly defined. 3,22,23 A total of 466 consecutive patients, with clinically suspected or biopsy-proven myocarditis, were enrolled in a single centre prospective study from 1992 to 2012. Survival free from death or heart transplantation at 10 years was 83% and was lower in biopsy-proven versus clinically suspected myocarditis (76% vs. 94%, p < 0.001). Female gender, fulminant presentation, anti-nuclear antibodies and lower LVEF were predictors of death or heart transplantation. 24

show abstract

Multi‐variable biomarker approach in identifying incident heart failure in chronic kidney disease: results from the Chronic Renal Insufficiency Cohort study

Cited by 11 publications

References 28 publications

A Bibliometric and Visualized Analysis of Uremic Cardiomyopathy From 1990 to 2021

A Bibliometric and Visualized Analysis of Uremic Cardiomyopathy From 1990 to 2021

Direct and indirect effects of fibroblast growth factor 23 on the heart

June 2022 at a glance: prevention, outcomes and treatment

Contact Info

Product

Resources

About